AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21231927 — intervention group
Group type: EXPERIMENTAL
Intervention: FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab)
Number of subjects: 52
Study 21231927 — intervention group
Group type: EXPERIMENTAL
Intervention: FCM
Number of subjects: 52
Study 21231927 — intervention group
Group type: EXPERIMENTAL
Intervention: FCM-R
Number of subjects: 52
Study 20030496 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of the diaphragm
Number of subjects: 0
Study 17177298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritherapy including amantadine (interferon, ribavirin, and amantadine)
Number of subjects: 2
Study 17177298 — intervention group
Group type: COMPARATOR
Intervention: Bitherapy (interferon and ribavirin)
Number of subjects: 2
Study 15189387 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based programme on aspects of EBP including literature searching and critical appraisal
Number of subjects: 30
Study 15189387 — intervention group
Group type: COMPARATOR
Intervention: Standard in-service training package on the management of common knee pathologies
Number of subjects: 30
Study 11438340 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI-ready sperm
Number of subjects: 209
Study 11438340 — intervention group
Group type: COMPARATOR
Intervention: Conventional sperm
Number of subjects: 209
Study 9602597 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 2 MAC of isoflurane in nitrous oxide
Number of subjects: 21
Study 9602597 — intervention group
Group type: COMPARATOR
Intervention: No volatile agent
Number of subjects: 21
Study 30799401 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 172
Study 30799401 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 172
Study 31577874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 24 mg
Number of subjects: 382
Study 31577874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 72 mg
Number of subjects: 382
Study 31577874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 240 mg
Number of subjects: 382
Study 31577874 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab 300 mg
Number of subjects: 382
Study 31577874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 28522352 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-influenza plasma plus standard care
Number of subjects: 98
Study 28522352 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 98
Study 25286891 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf compression sleeves
Number of subjects: 11
Study 23411647 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Number of subjects: 30
Study 23411647 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 30
Study 19175400 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 10 mg/kg twice daily (b.i.d.)
Number of subjects: 44
Study 19175400 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 20 mg/kg twice daily (b.i.d.)
Number of subjects: 44
Study 17557990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (22.5% protein)
Number of subjects: 120
Study 17557990 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (15% protein)
Number of subjects: 120
Study 17557990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 120
Study 15042007 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 385
Study 12498134 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40
Study 12498134 — intervention group
Group type: COMPARATOR
Intervention: Anaprilin
Number of subjects: 40
Study 9462907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexion night splints for 1 month
Number of subjects: 37
Study 8535099 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin converting enzyme inhibitor)
Number of subjects: 9
Study 8535099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8535099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnic hyperventilation
Number of subjects: 9
Study 2121911 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy radiation therapy (RT) to gonads (group 1)
Number of subjects: 60
Study 2121911 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal RT (group 2)
Number of subjects: 60
Study 2121911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial RT (group 3)
Number of subjects: 60
Study 2121911 — intervention group
Group type: EXPERIMENTAL
Intervention: Leydig cell function assessment (LH and testosterone)
Number of subjects: 60
Study 105834 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 13
Study 105834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 13
Study 105834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31682027 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular slow-release enteric-coated PAS 4 g twice daily
Number of subjects: 29
Study 31682027 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular slow-release enteric-coated PAS 8 g once daily
Number of subjects: 29
Study 31682027 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 29
Study 30806619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 487
Study 30806619 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 487
Study 28430910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin plus ezetimibe (intensive LDL-C lowering, target LDL-C < 70 mg/dL)
Number of subjects: 1734
Study 28430910 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin monotherapy (standard LDL-C lowering, target LDL-C 90-100 mg/dL)
Number of subjects: 1734
Study 28430910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin plus ezetimibe (in patients with higher cholesterol absorption)
Number of subjects: 1734
Study 25872666 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision of the pit of the sinus followed by phenol applications of the sinus tract
Number of subjects: 100
Study 25872666 — intervention group
Group type: COMPARATOR
Intervention: Radical surgical excision of the sinus
Number of subjects: 100
Study 23323901 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis checklists
Number of subjects: 17
Study 23323901 — intervention group
Group type: COMPARATOR
Intervention: Memory alone (no checklists)
Number of subjects: 17
Study 21113615 — intervention group
Group type: EXPERIMENTAL
Intervention: Racewalking at 10.9 ± 1.0 km h(‐1) (Walk)
Number of subjects: 9
Study 21113615 — intervention group
Group type: COMPARATOR
Intervention: Running at the same velocity (RunVel)
Number of subjects: 9
Study 21113615 — intervention group
Group type: EXPERIMENTAL
Intervention: Running at 13 ± 1.8 km h(‐1) (Run[Formula: see text])
Number of subjects: 9
Study 19111995 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality relaxation plus intravenous morphine PCA infusion
Number of subjects: 88
Study 19111995 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine PCA infusion alone
Number of subjects: 88
Study 17485449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 20
Study 17485449 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 20
Study 15297305 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intervention including group education meetings, consensus procedure on antibiotic indication and type, communication skills training, monitoring and feedback on prescribing behaviour, education for assistants and pharmacists, and educational material for patients.
Number of subjects: 100
Study 15297305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 15297305 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intervention
Number of subjects: 100
Study 15297305 — intervention group
Group type: COMPARATOR
Intervention: Multiple intervention and Control group
Number of subjects: 100
Study 11890487 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 to 5 mg/day
Number of subjects: 28
Study 11890487 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50 to 250 mg/day
Number of subjects: 28
Study 9673476 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylic acid 0.2% (PAA) gel
Number of subjects: 89
Study 9673476 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl alcohol 1.4% (PVA)
Number of subjects: 89
Study 7989638 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase sequential treatment strategy
Number of subjects: 119
Study 2692290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0
Study 2692290 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 0
Study 31578418 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care case John
Number of subjects: 0
Study 31578418 — intervention group
Group type: COMPARATOR
Intervention: Critical care case Jane
Number of subjects: 0
Study 31578418 — intervention group
Group type: EXPERIMENTAL
Intervention: Male responders
Number of subjects: 0
Study 31578418 — intervention group
Group type: COMPARATOR
Intervention: Female responders
Number of subjects: 0
Study 28121041 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibiotic prophylaxis (intravenous cefuroxime 750 mg plus metronidazole 500 mg, three times daily for 3 days after surgery)
Number of subjects: 150
Study 28121041 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis (single preoperative dose of cefazolin 2000 mg)
Number of subjects: 150
Study 28121041 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended antibiotic prophylaxis
Number of subjects: 150
Study 28121041 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis
Number of subjects: 150
Study 26501562 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 40
Study 26501562 — intervention group
Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 40
Study 23811059 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mailed personalized feedback
Number of subjects: 191
Study 23811059 — intervention group
Group type: COMPARATOR
Intervention: E-mailed generic feedback
Number of subjects: 191
Study 19939481 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1669
Study 19181821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (n = 83)
Number of subjects: 168
Study 19181821 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 85)
Number of subjects: 168
Study 17537011 — intervention group
Group type: EXPERIMENTAL
Intervention: Turquoise light (OSRAM L18W/860 fluorescent lamps)
Number of subjects: 0
Study 17537011 — intervention group
Group type: COMPARATOR
Intervention: Blue light (Philips TL20W/52 fluorescent lamps)
Number of subjects: 0
Study 14999598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha 2b plus ribavirin for 48 weeks
Number of subjects: 0
Study 14999598 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nondetectability of virus load in serum for 36 weeks
Number of subjects: 0
Study 14999598 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nondetectability of virus load in serum for 32 weeks
Number of subjects: 0
Study 12494609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion Avoidance (FA) On
Number of subjects: 38
Study 12494609 — intervention group
Group type: EXPERIMENTAL
Intervention: AICS activated
Number of subjects: 38
Study 9535545 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% pale sulfonated shale oil
Number of subjects: 20
Study 9535545 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hydrocortisone
Number of subjects: 20
Study 9535545 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (active ingredient-free)
Number of subjects: 20
Study 8845664 — intervention group
Group type: COMPARATOR
Intervention: Transfer Factor (TF), administered subcutaneously daily for 3 to 4 days during the acute phase, followed by maintenance dosages at 15-day intervals for the first 6 months and monthly thereafter.
Number of subjects: 20
Study 2667687 — intervention group
Group type: EXPERIMENTAL
Intervention: Heater probe therapy (n = 20)
Number of subjects: 43
Study 2667687 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n = 23)
Number of subjects: 43
Study 334217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine plus alcohol
Number of subjects: 9
Study 334217 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus alcohol
Number of subjects: 9
Study 334217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine alone
Number of subjects: 9
Study 30358697 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward Running Training (BRT)
Number of subjects: 43
Study 30358697 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward Running Training (FRT)
Number of subjects: 43
Study 30358697 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 43
Study 29153730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac (31.5 mg) with nitrous oxide/oxygen
Number of subjects: 102
Study 29153730 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline placebo with nitrous oxide/oxygen
Number of subjects: 102
Study 26293458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal referrals only
Number of subjects: 1090
Study 26293458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal referrals + a tailored mailed reminder
Number of subjects: 1090
Study 26293458 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal referrals + telephone health navigator
Number of subjects: 1090
Study 26293458 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1090
Study 26293458 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolved problems
Number of subjects: 1090
Study 24706338 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall physical activity
Number of subjects: 652
Study 24706338 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related physical activity
Number of subjects: 652
Study 24706338 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized sports
Number of subjects: 652
Study 24706338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative MET scores
Number of subjects: 652
Study 24706338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport-related physical activity in women
Number of subjects: 652
Study 24706338 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated traumatic events
Number of subjects: 652
Study 23147972 — intervention group
Group type: EXPERIMENTAL
Intervention: Strictly enforced smoke-free car policy
Number of subjects: 981
Study 23147972 — intervention group
Group type: COMPARATOR
Intervention: No smoke-free car policy
Number of subjects: 981
Study 23147972 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice for smoke-free car
Number of subjects: 981
Study 23147972 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger child and smoking ≤10 cigarettes per day
Number of subjects: 981
Study 20889877 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (2 mg/kg/day) plus folate (5 mg/day)
Number of subjects: 82
Study 20889877 — intervention group
Group type: COMPARATOR
Intervention: Folate alone
Number of subjects: 82
Study 17332786 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity (e.g., brisk walking for at least 30 min daily)
Number of subjects: 0
Study 17332786 — intervention group
Group type: EXPERIMENTAL
Intervention: More vigorous physical exercise or resistance training
Number of subjects: 0
Study 17332786 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured and low-intensity physical activity
Number of subjects: 0
Study 17332786 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of maximal oxygen consumption
Number of subjects: 0
Study 15964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine C(0) levels
Number of subjects: 334
Study 15964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine trough values
Number of subjects: 334
Study 15964332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine C(2) levels
Number of subjects: 334
Study 11836038 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined therapy
Number of subjects: 151
Study 11836038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 151
Study 11836038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 10530227 — intervention group
Group type: COMPARATOR
Intervention: Miniplates for internal rigid fixation
Number of subjects: 60
Study 10530227 — intervention group
Group type: EXPERIMENTAL
Intervention: Panfix lag screws for internal rigid fixation
Number of subjects: 60
Study 7489174 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical resection in patients with T4 tumors
Number of subjects: 289
Study 7489174 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 289
Study 7489174 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivisceral resection
Number of subjects: 289
Study 7489174 — intervention group
Group type: COMPARATOR
Intervention: Control group (T3N0M0 and T3N1M0 lesions)
Number of subjects: 289
Study 1827947 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and cyproterone acetate
Number of subjects: 99
Study 1827947 — intervention group
Group type: COMPARATOR
Intervention: Estradiol and norethisterone acetate
Number of subjects: 99
Study 1827947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 99
Study 7213581 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 degrees temperature
Number of subjects: 9
Study 7213581 — intervention group
Group type: COMPARATOR
Intervention: 28 degrees temperature
Number of subjects: 9
Study 30633542 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 10
Study 27522590 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-radius TKA (SR)
Number of subjects: 237
Study 27522590 — intervention group
Group type: COMPARATOR
Intervention: Multi-radius TKA (MR)
Number of subjects: 237
Study 26183793 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electrocardiographic monitoring with insertable cardiac monitors (ICM)
Number of subjects: 168
Study 26183793 — intervention group
Group type: COMPARATOR
Intervention: Single 24-hour Holter
Number of subjects: 168
Study 26183793 — intervention group
Group type: COMPARATOR
Intervention: Single 30-day event recorder
Number of subjects: 168
Study 26183793 — intervention group
Group type: COMPARATOR
Intervention: Quarterly 24-hour Holters
Number of subjects: 168
Study 26183793 — intervention group
Group type: COMPARATOR
Intervention: Quarterly 7-day monitors
Number of subjects: 168
Study 26183793 — intervention group
Group type: COMPARATOR
Intervention: All single external monitoring strategies
Number of subjects: 168
Study 26183793 — intervention group
Group type: COMPARATOR
Intervention: Repetitive periodic monitoring strategies
Number of subjects: 168
Study 24226492 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical block with levobupivacaine before the surgical incision
Number of subjects: 64
Study 24226492 — intervention group
Group type: COMPARATOR
Intervention: Morphine (standardized dose 30 minutes before the end of surgery)
Number of subjects: 64
Study 21279704 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT + radiotherapy (RT) + adjuvant chemotherapy (AC)
Number of subjects: 338
Study 21279704 — intervention group
Group type: COMPARATOR
Intervention: CCRT + AC
Number of subjects: 338
Study 19416133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole maintenance therapy for up to 82 months
Number of subjects: 195
Study 17522560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole 10-15 mg/day (n = 153)
Number of subjects: 448
Study 17522560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral haloperidol 7.5-10 mg/day (n = 151)
Number of subjects: 448
Study 17522560 — intervention group
Group type: COMPARATOR
Intervention: Oral aripiprazole
Number of subjects: 448
Study 17522560 — intervention group
Group type: COMPARATOR
Intervention: Oral haloperidol
Number of subjects: 448
Study 15374803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine therapy
Number of subjects: 0
Study 11396750 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 93
Study 11396750 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 93
Study 11396750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both heparins
Number of subjects: 93
Study 9738746 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (prospective study with regular evaluations)
Number of subjects: 0
Study 9738746 — intervention group
Group type: COMPARATOR
Intervention: Group II (non-prospective study)
Number of subjects: 0
Study 9738746 — intervention group
Group type: EXPERIMENTAL
Intervention: Older cohort
Number of subjects: 0
Study 9738746 — intervention group
Group type: COMPARATOR
Intervention: Younger cohort
Number of subjects: 0
Study 8031159 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + UFT (A)
Number of subjects: 39
Study 8031159 — intervention group
Group type: COMPARATOR
Intervention: MMC + 5-FU (B)
Number of subjects: 39
Study 3363755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 24
Study 3363755 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 24
Study 3363755 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of 5 m and 36 m
Number of subjects: 24
Study 29773326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (1 mg/kg bodyweight) and durvalumab (20 mg/kg bodyweight) every 4 weeks for four doses, followed by maintenance intravenous durvalumab at the same dose and schedule for nine doses
Number of subjects: 40
Study 29773326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab and durvalumab
Number of subjects: 40